NCT03503513View on ClinicalTrials.gov

Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 24, 2018

Primary Completion Date

September 8, 2023

Study Completion Date

September 30, 2023

Conditions
Urinary Tract InfectionsSpinal Cord InjuriesSpinal Cord DiseasesNeurogenic Bladder
Interventions
DRUG

Gentamicin Sulfate

Gentamicin is compounded by the Michigan Medicine Research Pharmacy in a concentration of 480 milligrams of the active product to 1000 milliliters of normal saline. Pharmacy mails participants treatment drug. Once received, participants will do daily instillations of 30 milliliters of solution after catheterizing their bladder at night.

Trial Locations (1)

48103

University of Michigan Health System, Ann Arbor

All Listed Sponsors
collaborator

Department of Health and Human Services

FED

lead

University of Michigan

OTHER

NCT03503513 - Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury | Biotech Hunter | Biotech Hunter